OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically significant and well-validated pharmacological pathways, with a focus on oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα).